Open-label placebo shows promise as therapy for disorders of gut-brain interaction in children

Pain-predominant disorders of gut-brain interaction (DGBIs) in children -; such as functional abdominal pain (FAP) and irritable bowel syndrome (IBS)-; can lead to disabling symptoms, poor quality of life and high use of health care resources. Studies suggest that an open-label placebo (OLP) approach -; in which patients are aware that they are receiving a placebo -; can benefit adults, but little is known about this in children. A group of investigators led by Boston Children’s Samuel Nurko, MD, MPH conducted the first OLP study in pediatrics in a multicenter randomized crossover trial published today in JAMA Pediatrics.

The study looked at 30 children between the ages of 8 and 18 who were diagnosed with IBS or FAP. The patients tracked their pain for seven days leading up to the study. They were then randomized to either a control or OLP group, with a crossover after three weeks.

Researchers explained the basic concept of a placebo and that they have been beneficial in some previous studies. Patients took 1.5 ml of an inert liquid placebo twice a day; this syrup mimicked the appearance of other medications used in pediatric care. All of the patients were given access to hyoscyamine for use as a rescue medication and kept symptom diaries throughout the study.

Nurko and his colleagues found that patients’ mean pain scores were significantly lower during the OLP treatment than during the control period; they also took nearly twice as many tablets of hyoscyamine during the control period than during the OLP period, and there were no side effects.

A significant placebo effect has been observed in double-blind clinical studies in children with DGBIs. It’s widely believed that concealment or deception is required to elicit a placebo response, but our study shows that the open administration of a placebo treatment -; i.e. non-concealed and without deception -; is effective. The exact nature of the response is still not known, but my hope is to be able to understand the process so we’ll be able to harness it and use in routine clinical care.”

Samuel Nurko, MD, MPH, Boston Children’s Hospital

The results of this first-of-its-kind study in pediatric patients with DGBIs show promise as a future non-pharmacologic therapy of these difficult-to-treat conditions.

Source:

Boston Children’s Hospital

Journal reference:

Nurko, S., et al. (2022) Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial. JAMA Pediatrics. doi.org/10.1001/jamapediatrics.2021.5750.

Baby News

Related Posts

High doses of antibiotic may safely and effectively treat TB meningitis

Comments Off on High doses of antibiotic may safely and effectively treat TB meningitis

Intervention to help parents prevent obesity in firstborn children benefits siblings

Comments Off on Intervention to help parents prevent obesity in firstborn children benefits siblings

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

Comments Off on NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

How to help your child who is socially anxious – CHOC

Comments Off on How to help your child who is socially anxious – CHOC

How to protect your kids from dog bites – CHOC

Comments Off on How to protect your kids from dog bites – CHOC

Childhood cancer diagnosis not delayed in Canada during the pandemic, study says

Comments Off on Childhood cancer diagnosis not delayed in Canada during the pandemic, study says

Less physical activity and more screen time impact children’s mental health during the pandemic

Comments Off on Less physical activity and more screen time impact children’s mental health during the pandemic

TEDDY study adds to a growing body of evidence that type 1 diabetes is not a single disease

Comments Off on TEDDY study adds to a growing body of evidence that type 1 diabetes is not a single disease

COVID-19 was the third leading cause of death in the US in 2020 and 2021

Comments Off on COVID-19 was the third leading cause of death in the US in 2020 and 2021

ED visits for pediatric poisonings increased nine times following cannabis legalization

Comments Off on ED visits for pediatric poisonings increased nine times following cannabis legalization

Researchers find an uptick in the use of school mental health services before the pandemic

Comments Off on Researchers find an uptick in the use of school mental health services before the pandemic

Administering flu vaccines to children having surgery substantially boosts vaccination rates

Comments Off on Administering flu vaccines to children having surgery substantially boosts vaccination rates

Create Account



Log In Your Account